Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04089358 | Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study | active not recruiting | Phase 3 | 387 | Children's Oncology GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT05171647 | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma(SUNMO) | active not recruiting | Phase 3 | 208 | Hoffmann-La Roche |
| 13 |
| Aug 5, 2026 |
| clinicaltrials |
| NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | recruiting | Phase 2 / Phase 3 | 312 | Moleculin Biotech, Inc.INDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT06895538 | Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy | recruiting | Phase 2 / Phase 3 | 24 | Peking University First HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07712588 | Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) | not yet recruiting | Phase 2 / Phase 3 | 880 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT01169337 | Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | active not recruiting | Phase 3 | 226 | National Cancer Institute (NCI)NIH | 3 | Aug 4, 2026 | clinicaltrials |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | active not recruiting | Phase 2 / Phase 3 | 363 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma(EPCORE™FL-2) | active not recruiting | Phase 3 | 1,095 | GenmabINDUSTRY | 32 | Aug 4, 2026 | clinicaltrials |
| NCT07188558 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy(PiNACLE-H2H) | recruiting | Phase 3 | 400 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07742215 | A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)(AMMADINA) | recruiting | Phase 3 | 390 | BiocadINDUSTRY | 2 | Aug 3, 2026 | clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT02443077 | Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | active not recruiting | Phase 3 | 94 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07740486 | A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease(TiTan) | not yet recruiting | Phase 3 | 248 | Polish Myeloma ConsortiumOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT03914625 | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | active not recruiting | Phase 3 | 6,720 | National Cancer Institute (NCI)NIH | 5 | Jul 30, 2026 | clinicaltrials |
| NCT04939090 | Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | active not recruiting | Phase 3 | 227 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05457556 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | active not recruiting | Phase 3 | 66 | Children's Oncology GroupNETWORK | 3 | Jul 30, 2026 | clinicaltrials |
| NCT07072585 | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | not yet recruiting | Phase 2 / Phase 3 | 1,708 | Children's Oncology GroupNETWORK | 0 | Jul 30, 2026 | clinicaltrials |
| NCT07735637 | A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).(DURGA-6) | not yet recruiting | Phase 3 | 750 | AstraZenecaINDUSTRY | 15 | Jul 30, 2026 | clinicaltrials |
| NCT02101853 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 669 | National Cancer Institute (NCI)NIH | 5 | Jul 29, 2026 | clinicaltrials |
| NCT02112916 | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | active not recruiting | Phase 3 | 847 | National Cancer Institute (NCI)NIH | 4 | Jul 29, 2026 | clinicaltrials |
| NCT02166463 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | active not recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 3 | Jul 29, 2026 | clinicaltrials |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma(iMMagine-3) | active not recruiting | Phase 3 | 452 | Kite, A Gilead CompanyINDUSTRY | 15 | Jul 29, 2026 | clinicaltrials |
| NCT07732712 | Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells | not yet recruiting | Phase 2 / Phase 3 | 15 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07735117 | Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML | not yet recruiting | Phase 3 | 168 | Ruijin HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT06319456 | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | recruiting | Phase 3 | 344 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07728188 | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 520 | AbbVieINDUSTRY | 13 | Jul 27, 2026 | clinicaltrials |
| NCT02970318 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | active not recruiting | Phase 3 | 310 | Acerta Pharma BVINDUSTRY | 25 | Jul 24, 2026 | clinicaltrials |
| NCT04212013 | A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | active not recruiting | Phase 3 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06764238 | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol(CCCG-I/HR-ALL) | recruiting | Phase 2 / Phase 3 | 1,800 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Jul 23, 2026 | clinicaltrials |
| NCT04285086 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance(SURPASS ET) | active not recruiting | Phase 3 | 174 | PharmaEssentiaINDUSTRY | 8 | Jul 22, 2026 | clinicaltrials |
| NCT04404283 | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL(ECHELON-3) | active not recruiting | Phase 3 | 239 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 14 | Jul 22, 2026 | clinicaltrials |
| NCT05735834 | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients(RITZ) | active not recruiting | Phase 3 | 122 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 8 | Jul 22, 2026 | clinicaltrials |
| NCT06072131 | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL(CRESCENDO) | recruiting | Phase 3 | 504 | Acrotech Biopharma Inc.INDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT07719855 | A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma | not yet recruiting | Phase 3 | 652 | Ruijin HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07712848 | DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | recruiting | Phase 3 | 291 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02416388 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR(BIG-1) | recruiting | Phase 2 / Phase 3 | 3,100 | University Hospital, AngersOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
| NCT03020030 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | active not recruiting | Phase 3 | 560 | Dana-Farber Cancer InstituteOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT04483739 | Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)(IsKia) | active not recruiting | Phase 3 | 302 | European Myeloma Network B.V.NETWORK | 8 | Jul 16, 2026 | clinicaltrials |
| NCT04717414 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions(INDEPENDENCE) | active not recruiting | Phase 3 | 313 | CelgeneINDUSTRY | 26 | Jul 16, 2026 | clinicaltrials |
| NCT07649525 | Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level(iFIT) | recruiting | Phase 3 | 1,226 | University of LeedsOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06652633 | Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies(Hesperia) | recruiting | Phase 3 | 546 | Lakefront Biotherapeutics NVINDUSTRY | 5 | Jul 13, 2026 | clinicaltrials |
| NCT04712097 | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma(Celestimo) | active not recruiting | Phase 3 | 478 | Hoffmann-La RocheINDUSTRY | 15 | Jul 10, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT06508983 | A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients | recruiting | Phase 3 | 360 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04576156 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | active not recruiting | Phase 3 | 327 | Geron CorporationINDUSTRY | 26 | Jul 8, 2026 | clinicaltrials |
| NCT04685616 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma(RADAR) | recruiting | Phase 3 | 1,042 | University College, LondonOTHER | 12 | Jul 8, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05409066 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma(EPCORE FL-1) | active not recruiting | Phase 3 | 549 | GenmabINDUSTRY | 30 | Jul 8, 2026 | clinicaltrials |
| NCT07572123 | Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 374 | National Cancer Institute (NCI)NIH | 0 | Jul 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 6, 2026source: clinicaltrials